drugset / Trial / NCT06295692

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

NCT06295692

Phase 3 Active not recruiting 19 enrolled Janssen Pharmaceutical K.K.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).

Timeline

Start
2024-02-09
Primary completion
2025-01-14
Completion
2027-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotrokinra Peptide Oral